

U.S.S.N. 10/099,830

Filed: March 13, 2002


AMENDMENT AND RESPONSE TO OFFICE ACTION**Remarks****Rejection Under 35 U.S.C. § 112, first paragraph**

Claims 34, 41-44 and 46 were rejected under 35 U.S.C. § 112, first paragraph, as not being enabled. Applicants respectfully traverse this rejection to the extent that it is applied to the claims as amended. Claim 34 has been amended to recite a therapeutic system comprising a prodrug which is converted to a substantially cytotoxic drug by the action of NQO2 wherein the prodrug is CB 1954. Claims 46 and 47 have been canceled.

The Examiner's rejection of claims 34, 41-44, and 46 is now moot as the Examiner agreed, in the office action mailed on January 18, 2005, that the specification is enabled for a therapeutic system comprising CB 1954 (page 2, first paragraph under Rejections Maintained).

Allowance of claims 34 and 41-44 is respectfully solicited.

Respectfully submitted,


Patrea L. Pabst
Reg. No. 31,284

Date: May 18, 2005

PABST PATENT GROUP LLP
400 Colony Square, Suite 1200
1201 Peachtree Street
Atlanta, Georgia 30361
(404) 879-2151
(404) 879-2160 (Facsimile)

45054721

4

ERD 100 CON
078230/00031